Vitamin Shoppe Inc (VSI) Given Average Recommendation of “Hold” by Brokerages

Shares of Vitamin Shoppe Inc (NYSE:VSI) have earned an average rating of “Hold” from the nine ratings firms that are covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell rating and four have given a hold rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $4.95.

VSI has been the subject of several recent research reports. Zacks Investment Research downgraded shares of Vitamin Shoppe from a “hold” rating to a “sell” rating in a report on Friday, March 2nd. ValuEngine downgraded shares of Vitamin Shoppe from a “hold” rating to a “sell” rating in a report on Friday, June 1st. Finally, Morgan Stanley dropped their target price on shares of Vitamin Shoppe from $4.00 to $3.75 and set an “equal weight” rating for the company in a report on Wednesday, February 28th.

In other news, Chairman Alex Smith purchased 12,666 shares of the firm’s stock in a transaction on Tuesday, May 29th. The shares were bought at an average cost of $5.24 per share, with a total value of $66,369.84. Following the purchase, the chairman now directly owns 19,118 shares of the company’s stock, valued at $100,178.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Guillermo Marmol purchased 20,000 shares of the firm’s stock in a transaction on Friday, May 25th. The shares were purchased at an average cost of $5.15 per share, for a total transaction of $103,000.00. Following the completion of the purchase, the director now directly owns 29,631 shares in the company, valued at $152,599.65. The disclosure for this purchase can be found here. Insiders have acquired a total of 190,053 shares of company stock valued at $805,158 over the last 90 days. 18.50% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in VSI. GSA Capital Partners LLP acquired a new stake in shares of Vitamin Shoppe during the 1st quarter worth about $109,000. Lazard Asset Management LLC acquired a new stake in shares of Vitamin Shoppe during the 4th quarter worth about $115,000. Crossmark Global Holdings Inc. boosted its stake in shares of Vitamin Shoppe by 122.8% during the 4th quarter. Crossmark Global Holdings Inc. now owns 31,320 shares of the specialty retailer’s stock worth $138,000 after purchasing an additional 17,260 shares during the last quarter. Macquarie Group Ltd. boosted its stake in shares of Vitamin Shoppe by 180.2% during the 4th quarter. Macquarie Group Ltd. now owns 52,681 shares of the specialty retailer’s stock worth $232,000 after purchasing an additional 33,881 shares during the last quarter. Finally, Pinebridge Investments L.P. boosted its stake in shares of Vitamin Shoppe by 28.3% during the 4th quarter. Pinebridge Investments L.P. now owns 63,860 shares of the specialty retailer’s stock worth $281,000 after purchasing an additional 14,079 shares during the last quarter. 88.46% of the stock is currently owned by institutional investors.

Shares of Vitamin Shoppe traded down $0.20, reaching $7.45, during trading hours on Thursday, according to MarketBeat Ratings. The company had a trading volume of 459,500 shares, compared to its average volume of 580,292. The company has a quick ratio of 0.44, a current ratio of 1.88 and a debt-to-equity ratio of 0.47. Vitamin Shoppe has a 12-month low of $2.95 and a 12-month high of $12.00. The company has a market capitalization of $180.52 million, a PE ratio of 19.41 and a beta of 0.51.

Vitamin Shoppe (NYSE:VSI) last posted its earnings results on Wednesday, May 9th. The specialty retailer reported $0.10 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.10. Vitamin Shoppe had a negative net margin of 22.80% and a positive return on equity of 1.28%. The firm had revenue of $295.96 million during the quarter, compared to the consensus estimate of $293.44 million. research analysts anticipate that Vitamin Shoppe will post -0.21 EPS for the current year.

About Vitamin Shoppe

Vitamin Shoppe, Inc, through its subsidiaries, operates as a omni-channel specialty retailer and contract manufacturer of nutritional products in the United States and internationally. It operates in two segments, Retail and Manufacturing. The company provides custom manufacturing and private labeling services for vitamin, mineral, and supplement products, as well as develops and markets own branded products.

Analyst Recommendations for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply